ProfoundBio’s Post

ProfoundBio is thrilled to announce the initiation of dosing in the Phase 1/2 clinical trial of PRO1107, marking a significant step forward in our efforts to develop antibody-drug conjugates (ADCs) with improved clinical outcomes for cancer patients. PRO1107 is a pioneering Protein Tyrosine Kinase 7 (PTK7)-targeted ADC that leverages our novel, proprietary hydrophilic MMAE-based linker-drug, aiming to set new standards in safety and efficacy for MMAE-based ADCs in the fight against cancer. A heartfelt thank you to our dedicated investigators and the patients participating in this trailblazing research. Your involvement is pivotal in driving forward our mission to deliver groundbreaking treatments. Read more: https://lnkd.in/gKXsEwsB #ProfoundBio #ClinicalTrial #CancerResearch #InnovationInOncology #BiotechLinkedIn